This post is presented by our media partner Cannabis News Wire
View the original article here.
- Lexaria, a global innovator in drug delivery platforms, just announced its newest relationship with the National Research Council of Canada (“NRC”)
- Specific molecular characteristics of the glucagon-peptide 1 (“GLP-1”) drug, semaglutide, processed with Lexaria’s patented DehydraTECH(TM) technology, will be evaluated
- Previous research has shown that using a DehydraTECH-semaglutide capsule composition yields a 43% higher peak level of semaglutide in blood compared to Rybelsus(R). This has potential for increased weight-loss and diabetic control
- Lexaria’s management is confident that this partnership will complement the company’s animal and human pharmacokinetic and pharmacodynamic studies for the 2024 calendar year
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced a partnership with the National Research Council of Canada (“NRC”) that will pursue an applied research program to evaluate specific molecular characteristics of the company’s patented DehydraTECH(TM) technology processed with glucagon-peptide 1 (“GLP-1”) drug, semaglutide, related to its mode of action and performance (https://cnw.fm/tFjNC).
The work program will utilize simulated gastric fluid, mimicking conditions in the human gut. In addition, various testing methods will be employed, among them size exclusion chromatography (“SEC”), polyacrylamide gel electrophoresis (“PAGE”), dynamic light scattering (“DLS”), and matrix-assisted laser desorption ionization mass spectrometry (“MALDI MS”).
GLP-1 drugs have shown significant benefits in weight management and addressing diabetes. Previous research has shown that using a DehydraTECH-semaglutide capsule composition yields a 43% higher peak level of semaglutide in blood than an unprocessed Rybelsus(R) tablet. The benefits also extend to doing away with painful injections, which are the norm with GLP-1 delivery.
Lexaria’s management believes this partnership could help fast-track the company’s push for the adoption of DehydraTECH with GLP-1 drugs. It will also be integral in showcasing the potential of the technology while inching the company closer to tapping into an industry projected to be valued at $133.5 billion by 2030 (https://cnw.fm/GjFj1).
“We are excited about our partnership with the NRC for the mode of action molecular characterization of DehydraTECH-GLP-1 drugs. This work program could potentially provide data to assist Lexaria’s efforts in partnering with the pharmaceutical industry for the most rapid introduction possible of DehydraTECH with GLP-1 drugs,” noted John Docherty, Lexaria’s president.
This partnership follows Lexaria’s resolve to double down on GLP-1 studies for the 2024 calendar year. It also follows the recent independent third-party ethics review board approval for its GLP-1 human pilot study #2, which seeks to explore the oral delivery of GLP-1 drugs. In addition, in March Lexaria announced details of its WEIGHT-A24-1 animal study which will examine diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and DehydraTECH-processed cannabidiol, alone and in combination (https://cnw.fm/Qdt0X).
Lexaria’s management is confident that by identifying the molecular behavior of DehydraTECH-processed pure semaglutide compositions, the findings will complement the company’s animal and human pharmacokinetic and pharmacodynamic studies for the 2024 calendar year. In addition, it is hopeful that this could ultimately lead to alternative formulations with enhanced performance. The program is expected to be completed in early August, with results reported as soon as possible after that.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is powered by IBN
This post was originally published by our media partner here.
